HPMC – Hydroxypropylmethylcellulose

Abstract Forty-eight (48) drug products (DPs) containing amorphous solid dispersions (ASDs) have been approved by the U.S. Food and Drug Administration in the 12-year period between 2012 and 2023. These DPs comprise 36 unique amorphous drugs. Ten (10) therapeutic categories are represented, with…
Read More...

Abstract The influence of hydroxypropyl cellulose type (HPC-SSL SFP, HPC-SSL), concentration (2 %, 3.5 %, 5 %) and filler (lactose, calcium hydrogen phosphate (DCP)/microcrystalline cellulose (MCC)) on twin-screw wet granulation and subsequent tableting was studied. The aim was to identify the…
Read More...

Abstract This study focuses on the combination of three-dimensional printing (3DP) and amorphous solid dispersion (ASD) technologies for the manufacturing of gastroretentive floating tablets. Employing hot melt extrusion (HME) and fused deposition modeling (FDM), the study investigates the…
Read More...

Introduction TYLOPUR® is Hypromellose (HPMC) and a versatile pharmaceutical excipient. TYLOPUR® is manufactured at Tyloshin 2 plant at SE Tylose GmbH & Co. KG in Wiesbaden, Germany. This plant operates under GMP conditions and fulfills the requirements of the pharmaceutical industry. SE Tylose…
Read More...

Abstract Glidant used for the purpose of powder flowability enhancement is well known within the pharmaceutical industry to improve tablet manufacturing. Despite the widespread use of glidant for this purpose, the effect of glidant on the effect of tableting behavior is not well studied. To address…
Read More...

SYNOPSIS Controlled release (CR) formulations are revolutionizing drug delivery across the pharmaceutical landscape. Offering advantages like enhanced therapeutic outcomes and patient convenience, this innovative drug formulation is experiencing rapid global growth. The popularity of CR…
Read More...

Abstract The use of a process analytical technology has been demonstrated using near-infrared spectroscopy for continuous manufacturing of pharmaceutical formulations and is within the scope of the U.S. Food and Drug Administration's real-time release testing initiative. While effective for simple…
Read More...

IFF officially release a new Controlled release platform on 15th of May 2024. Here you get a deeper insight in the  "Timing is Everything" platform where you can learn about pharmaceutical formulations to benefit patients and the importance of controlled release of active ingredients. No…
Read More...

Abstract In the nasal cavity, nasal mucosa had a high blood perfusion rate, due to this the absorption of the drug is high as compared to other routes, as well as has increased good bioavailability of drugs at the systemic circulation. To improve the nasal retention time of in-situ gel with nasal…
Read More...

Orodispersible films (ODFs) have emerged as innovative pharmaceutical dosage forms, offering patient-specific treatment through adjustable dosing and the combination of diverse active ingredients. This expanding field generates vast datasets, requiring advanced analytical techniques for deeper…
Read More...